Price Range (₹)
Price Range (₹)
Issue Size (₹ in Cr.)
Minimum Quantity
Bidding Period
One of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (“APIs”), with a focus on research and development. As of March 31, 2021, they have niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti allergic.
Were among the largest exporters of Salbutamol Sulphate from India in Fiscal 2020 in terms of volume (Source: CRISIL Report as per Company DRHP).
Significant scale with leadership position across key & niche products
The company believes their core strength lies in identifying generic molecules (off-patent) in the existing therapeutic segments which fits in to existing chemistry and production infrastructure and their ability to develop the product and scale-up production.
Backward integrated business model
As on May 2021, 11 of the existing products were backward integrated, which contributed 63.25% of the total revenue for nine months period ended December 31, 2020.
Geographically diversified revenues with a global presence across 78 countries
Customers include global pharma companies such as Syntec Do Brasil LTDA, American International Chemical Inc and AT Planejamento E Desenbolvimento De Negocios Ltda etc.
The business is subject to extensive regulation
Failure to comply with regulations prescribed by governments and regulatory agencies or to obtain, maintain or renew statutory and regulatory licenses, permits and approvals required to operate business, results of operations and financial condition could be adversely affected.
Manufacturing or quality control problems in such an industry may be detrimental
Such events may damage the company's reputation and expose them to litigation or other liabilities, which could adversely affect the results of operations and financial condition.
Global pharmaceutical market to grow at steady ~5.3% CAGR over the next five years
Global pharmaceutical market has grown by around 5.5-6.0% CAGR from ~USD 925 billion in CY14 to ~USD 1,300 billion in CY20. It is expected to sustain this growth over the next five years to reach USD 1,630-1,730 billion in CY25. (Source: Company DRHP).
Active pharmaceutical ingredients (APIs) form the major cost for formulation players
The raw material cost also includes the cost for inert materials i.e the materials used to stabilise the impact of APIs and preserve them for a longer period of time. However, the inert material cost does not form more than 10% of the overall raw materials.
Shareholder | |
Retail Individual Investor | |
Non-Institutional Investor | |
Qualified Institutional Buyers | |
Employee | |
Overall |
Applications
refunds
Convenient investments
of application
For ICICI Bank linked A/c
For non ICICI Bank A/c
Go to the IPO section, select the IPO you want to apply from the list and click on ‘Apply’.
Fill in the quantity of the number of shares you want to buy. To apply at maximum price, check the cut-off price box and amount is auto calculated. If you want to apply at some other price within the price band, then you can enter the price manually by clicking on “Add bid” option.
Click on proceed to confirm the order. You can view the placed order under “order book”.
Choose the IPO you want to apply from the list. Click on Apply.
Fill in the quantity of shares. To apply at maximum price, check the cut-off price box and amount is auto calculated. If you want to apply at some other price within the price band, then you can enter the price manually by clicking on “Add bid” option.
Check the A/C, UPI details and click on proceed. You will get an UPI link by which payment can be made.
Trusted by
customers
Investments & Liability Products
Investment Basket
Access to
Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.